Travast

Trapost OSD is a prostaglandin analogue. It works as a selective FP prostanoid receptor agonist and is believed to lower intraocular pressure (IOP) by increasing the outflow of fluid through the uveoscleral pathway. Trapost OSD is an isopropyl ester prodrug: once absorbed through the cornea, it is broken down by esterase enzymes in the cornea into its biologically active free acid form.

In controlled clinical trials of Trapost OSD 0.004% ophthalmic solution, the most common adverse reaction was ocular hyperemia (redness of the eye), reported in 30% to 50% of patients. Up to 3% of patients stopped treatment because of conjunctival hyperemia. Ocular adverse reactions reported in 5% to 10% of patients in these trials included decreased visual acuity, eye discomfort, foreign body sensation, pain, and pruritus (itching). Ocular adverse reactions reported in 1% to 4% of patients in clinical trials with Trapost OSD 0.004% ophthalmic solution included abnormal vision, blepharitis, blurred vision, cataract, conjunctivitis, corneal staining, dry eye, iris discoloration, keratitis, lid margin crusting, ocular inflammation, photophobia, subconjunctival hemorrhage, and tearing. Non-ocular adverse reactions reported in 1% to 5% of patients in these clinical studies were allergy, angina pectoris, anxiety, arthritis, back pain, bradycardia, bronchitis, chest pain, cold/flu syndrome, depression, dyspepsia, gastrointestinal disorder, headache, hypercholesterolemia, hypertension, hypotension, infection, pain, prostate disorder, sinusitis, urinary incontinence, and urinary tract infections.